FLR

Fluor Corporation (FLR) Q3 2026 Earnings Call Transcript

IRVING, Texas--(BUSINESS WIRE)--Fluor Corporation (NYSE: FLR) announced financial results for its third quarter ended September 30, 2026. “Our third quarter results reflect strong demand across our key markets and continued progress converting our prospect pipeline into high-quality awards,” said Jim Breuer, chief executive officer of Fluor. “New awards of $10.9 billion, including LNG Canada Phase 2 as well as two mining projects, was the highest quarterly total in Fluor's history and grew back.

FLR's Q3 earnings may gain from mining, nuclear and EPC projects, but Energy Solutions transitions and fading project closeout benefits pose risks to margins.

Here is how Fluor (FLR) and Legence (LGN) have performed compared to their sector so far this year.

FLR's JGC joint venture will execute LNG Canada Phase 2, with Fluor set to recognize a $7.5 billion share as production capacity is poised to double.

SHEL greenlights LNG Canada Phase 2, doubling capacity to 28 mtpa and securing nearly 6 mtpa of additional LNG from the project.

The owners and operators of commercial reactors in the U.S. are planning for a larger and longer-lasting fleet. A recent survey of utility companies from the Nuclear Energy Institute (NEI) highlights rising interest in new reactors and expectations for operating lives beyond 80 years.

Here is how Fluor (FLR) and Owens Corning (OC) have performed compared to their sector so far this year.

CALGARY, Alberta — September 10 , 2026 — Leads & Copy — Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF), a Canadian company focused on developing pharmaceutical-grade barium and iodine contrast media for medical imaging, has achieved its first milestone under a non-dilutive Collaboration and Funding Agreement with Bayer AG. The company announced that it successfully submitted a complete feasibility work plan and timetable, which has been approved by Bayer. The milestone achievement triggers the first major non-dilutive payment of USD $1,000,000 from Bayer. This payment, combined with the initial USD $350,000 received on March 31, 2026, brings the total funding received by Voyageur from Bayer to USD $1,350,000 of the committed USD $2,350,000.

CALGARY, Alberta – TheNewswire - September 9, 2026 – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC Pink: VYYRF) (“ Voyageur ” or the “ Company ”), a Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical imaging, is pleased to announce that it has achieved the first milestone under its non-dilutive Collaboration and Funding Agreement with Bayer AG (“ Bayer ”) dated February 10, 2026 (the  “ Agreement ”) by submitting a complete feasibility work plan and timetable which has been approved by Bayer. (Collaboration funding news https://finance.yahoo.com/news/voyageur-pharmaceuticals-announces-collaboration-bayer-144926270.html )